Related Experiment Video
Updated: Feb 7, 2026

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
Published on: October 24, 2015
NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis
Li-Li Wu1, Wen-Pin Cai2, Xin Lei3
1Department of Clinical Laboratory, The central hospital of Wenzhou, The Dingli Clinical College of Wenzhou Medical University, Wenzhou, China.
Abstract:
Recent studies have shown that long non-coding RNAs (lncRNAs) play a pivotal role in the pathogenesis and progression of hepatocellular carcinoma (HCC). However, the biological action and potential mechanism of liver cancer cell drug resistance have not been clearly clarified. In this study, lncRNAs were screened and differentially expressed in parental and cisplatin-resistant cell lines (HepG2 and HepG2/CDDP). A novel lncRNA, termed NRAL (Nrf2 regulation-associated lncRNA), was identified, and the initial results indicated that it was highly expressed in HepG2 cisplatin resistant cell lines compared to their parental counterparts. Functionally, NRAL depletion significantly enhanced CDDP-mediated cytotoxicity and apoptosis in two cisplatin-resistant HCC cell lines. Mechanistically, the results indicated that NRAL regulates Nrf2 expression through miR-340-5p serving as a competing endogenous RNA (ceRNA), thus influencing the CDDP-induced phenotype in HCC. Collectively, the present investigation suggest that the NRAL/miR-340-5p/Nrf2 axis mediates cisplatin resistance in HCC, which may provide novel targets for overcoming cisplatin resistance in hepatocellular carcinoma cells.
Insights
A novel long non-coding RNA, NRAL, promotes cisplatin resistance in hepatocellular carcinoma (HCC) by regulating the miR-340-5p/Nrf2 pathway. Depleting NRAL sensitizes liver cancer cells to chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Long non-coding RNAs (lncRNAs) are implicated in hepatocellular carcinoma (HCC) pathogenesis.
- The precise mechanisms of drug resistance in liver cancer cells, particularly concerning lncRNAs, remain incompletely understood.
Purpose of the Study:
- To identify and characterize novel lncRNAs involved in cisplatin resistance in HCC.
- To elucidate the molecular mechanism by which NRAL influences chemotherapy response in liver cancer.
Main Methods:
- Screening of differentially expressed lncRNAs in parental and cisplatin-resistant HCC cell lines (HepG2 and HepG2/CDDP).
- Functional assays involving NRAL depletion to assess its impact on chemosensitivity and apoptosis.
- Investigation of the NRAL/miR-340-5p/Nrf2 regulatory axis using molecular biology techniques.
Main Results:
- A novel lncRNA, NRAL (Nrf2 regulation-associated lncRNA), was identified and found to be highly expressed in cisplatin-resistant HCC cells.
- NRAL depletion significantly increased cisplatin-induced cytotoxicity and apoptosis in resistant HCC cell lines.
- NRAL functions as a competing endogenous RNA (ceRNA) for miR-340-5p, thereby regulating Nrf2 expression and influencing the response to cisplatin.
Conclusions:
- The NRAL/miR-340-5p/Nrf2 axis is a key mediator of cisplatin resistance in hepatocellular carcinoma.
- NRAL represents a potential therapeutic target for overcoming drug resistance in HCC treatment.
Related Concept Videos
Hypothalamic-Pituitary Axis
Perpendicular-Axis Theorem
Consider a circular disc of mass M and radius R lying along an x-y plane. The origin lies at the center of the disc, and the z-axis is perpendicular to the disc's plane. All three axes coincide at the disc's center. The moment of inertia of this...
Parallel-axis Theorem
Moment of a Force About an Axis: Scalar
To better understand the concept of moment of force, consider the example of a cyclist riding a bicycle. When the cyclist applies force on...
Moment of a Force About an Axis: Vector
First, establish a coordinate system to understand how the moment of a force...
Moment of Inertia about an Arbitrary Axis
In this scenario, the perpendicular distance between the chosen arbitrary axis...

